TriVascular Technologies Inc

TriVascular Technologies — Merger or Acquisition (October 2015)

16 slides from TriVascular Technologies's merger presentation, Oct 27, 2015

  1. Slide 1: Combining innovation leaders to revolutionize aortic treatments

    Combining innovation leaders to revolutionize aortic treatments October 26, 2015 Filed by Endologix, Inc. Pursuant to Rule 425 Under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: TriVascular Technologies, Inc. Commission F

  2. Slide 2: Forward-Looking Statements and Additional Information

    Endologix and TriVascular will remain separate operational entities until the closing of the proposed merger transaction. Until closing, Endologix will not offer TriVascular products and TriVascular will not offer Endologix products. The offering referenced herein is not contingent upon the closing

  3. Slide 3: Treat more patients more effectively: The New Endologix will…

    Treat more patients more effectively The New Endologix will…

  4. Slide 4: Reason for the proposed merger

    Combining innovation leaders to revolutionize aortic treatments | 10.26.15 Reason for the proposed merger We will provide excellent service and support We will continue to uniquely pursue physician-driven innovation We will pioneer and deliver durable EVAR and EVAS solutions We will provide the broa

  5. Slide 5: Benefits of the proposed merger

    Benefits of the proposed merger Combining innovation leaders to revolutionize aortic treatments | 10.26.15 Patients Broadest indications for more on-label treatments Complex AAA and TAA solutions Enabling individualized AAA treatment Customers Aortic innovation leader with 370 patents and robust pip

  6. Slide 6: AAA disease requires multiple solutions

    AAA disease requires multiple solutions

  7. Slide 7: Merger will create one company with multiple AAA treatment options

    Merger will create one company with multiple AAA treatment options Combining innovation leaders to revolutionize aortic treatments | 10.26.15 CAUTION: Nellix is an investigational Device. Limited by federal (United States) law to investigational use only.

  8. Slide 8: EVAR and EVAS: innovative products with broad clinical indications

    EVAR Innovative products with broad clinical indications Ultra-low profile Narrow & tortuous iliacs Complex necks Reverse taper Combining innovation leaders to revolutionize aortic treatments | 10.26.15 Preserve bifurcation Tight distal aorta Reverse taper Thrombus EVAS Complete AAA sealing Iliac an

  9. Slide 9: Strong Revenue Growth with a Combined CAGR of 28%

    Strong Revenue Growth with a Combined CAGR of 28% Revenue $millions 180 152 111 89 Combining innovation leaders to revolutionize aortic treatments | 10.26.15

  10. Slide 10: TriVascular Ovation Prime System

    TriVascular Ovation Prime® System Lowest profile FDA-approved catheter Broadest FDA approved IFU Polymer sealing ring creates custom seal and protects the aortic neck Conformable, kink resistant iliac limbs Excellent safety and effectiveness data, including patients with challenging anatomic charact

  11. Slide 11: Endologix AFX2

    Endologix AFX2® Broad anatomical applicability Tight distal aortas Thrombus laden necks Anatomical fixation with unibody design Preserves native bifurcation Eliminates gate cannulation and limb competition ActiveSeal can extend the effective seal zone beyond the neck Intuitive, streamlined deploymen

  12. Slide 12: Endologix Nellix

    Endologix Nellix® Nellix is designed to: Treat more patients Wide patient applicability Complex AAA Simplify procedure and planning Limited SKUs More predictable procedure times Intellix™ case planning and management software Reduce endoleaks and secondary interventions Potential to reduce the total

  13. Slide 13: Significant Clinical Evidence (post merger)

    Significant Clinical Evidence* (post merger) 2015 2016 2017 Ovation IDE/CAP/PAS (2010) 320 320 320 Global Registry (2011) 501 501 501 LIFE (2014) 200 250 250 LUCY (2015) 20 225 225 Total 1,041 1,296 1,296 AFX IDEs (2000) 707 707 707 PEVAR (2010) 192 192 192 LEOPARD (2015) 150 800 800 Total 1,049 1,6

  14. Slide 14: Expanded global sales and clinical support (post merger)

    Expanded global sales and clinical support (post merger) World-class team of trained sales representatives and clinical specialists Customers in 44 countries across five continents Combining innovation leaders to revolutionize aortic treatments | 10.26.15 Both

  15. Slide 15: Deep pipeline of new aortic technologies (post merger)

    Deep pipeline of new aortic technologies* (post merger) Combining innovation leaders to revolutionize aortic treatments | 10.26.15 * Post-merger estimated regulatory approvals U.S. Europe Asia Pacific Latin America 2015 2016 2017 2018 2019 2020 (Japan) (China) (Japan) (Brazil) (Argentina) (Japan) (B

  16. Slide 16: Creating a leader in growth and innovation

    Creating a leader in growth and innovation that will offer Combining innovation leaders to revolutionize aortic treatments | 10.26.15 Broadest AAA product line Expanded global clinical support Multiple new aortic technologies Significant clinical evidence

TriVascular Technologies — Merger or Acquisition (October 2015) on 6ix